KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Accumulated Expenses (2016 - 2024)

Historic Accumulated Expenses for Astrazeneca (AZN) over the last 10 years, with Q4 2024 value amounting to $6.5 billion.

  • Astrazeneca's Accumulated Expenses rose 574.28% to $6.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $6.5 billion, marking a year-over-year increase of 574.28%. This contributed to the annual value of $6.5 billion for FY2024, which is 574.28% up from last year.
  • Latest data reveals that Astrazeneca reported Accumulated Expenses of $6.5 billion as of Q4 2024, which was up 574.28% from $6.1 billion recorded in Q4 2023.
  • In the past 5 years, Astrazeneca's Accumulated Expenses registered a high of $6.5 billion during Q4 2024, and its lowest value of -$911.0 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $4.5 billion, with a median of $5.6 billion in 2021.
  • In the last 5 years, Astrazeneca's Accumulated Expenses plummeted by 300.55% in 2020 and then surged by 4466.07% in 2021.
  • Astrazeneca's Accumulated Expenses (Quarter) stood at $3.9 billion in 2020, then skyrocketed by 44.66% to $5.6 billion in 2021, then decreased by 1.73% to $5.6 billion in 2022, then rose by 10.11% to $6.1 billion in 2023, then grew by 5.74% to $6.5 billion in 2024.
  • Its Accumulated Expenses was $6.5 billion in Q4 2024, compared to $6.1 billion in Q4 2023 and $5.6 billion in Q4 2022.